BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors
November 07 2018 - 4:49PM
BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan
Rietiker has been elected to BioTelemetry’s Board of Directors.
Dr. Rietiker was most recently the Chief
Executive Officer of LifeWatch AG, until it was acquired by
BioTelemetry in August 2017. Prior to becoming CEO of
LifeWatch AG in 2014, Dr. Rietiker held executive roles at Roche,
Boehringer Mannheim, Schering Plough, Covance and as CEO of
Centerpulse (formerly Sulzer Medica). Additionally, he has
been an investor, executive and Board Member of several
developmental-stage companies and has been a Senior Advisor to
Brown Brothers Harriman’s M&A practice.
Dr. Rietiker, a Swiss-US dual citizen, is a
trained physician with a doctorate from the University of Zurich,
Switzerland, and is also qualified to practice medicine in the
United States.
Joseph Capper, President and Chief Executive
Officer of BioTelemetry commented, “We are extremely pleased and
honored to welcome Steve to the Board of Directors. His
active participation was vital to the highly successful merger and
integration of LifeWatch into BioTelemetry. Steve’s proven
leadership, in-depth understanding of the healthcare industry and
experience in global markets make him an ideal addition to our
Board.”
About BioTelemetry
BioTelemetry, Inc. is the leading remote and
wireless medical technology company focused on delivery of health
information to improve quality of life and reduce cost of
care. We provide cardiac monitoring, mobile blood glucose
monitoring, centralized medical imaging, and original equipment
manufacturing that serves both the Healthcare and Clinical Research
industries. More information can be found at
www.gobio.com.
Contact:
BioTelemetry, Inc.Heather C. GetzInvestor RelationsExecutive
Vice President, Chief Financial
Officer800-908-7103investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024